Apoptosis: Targets in pancreatic cancer

被引：119

作者：

Sabine Westphal

Holger Kalthoff

机构：

[1] Department of Molecular Oncology, Clinic for General/Thoracic Surgery, University of Kiel, 24105 Kiel

来源：

Molecular Cancer | / 2卷 / 1期

关键词：

Apoptosis; Oncologic therapies; Pancreatic cancer;

D O I：

10.1186/1476-4598-2-6

中图分类号：

学科分类号：

摘要：

Pancreatic adenocarcinoma is characterized by poor prognosis, because of late diagnosis and lack of response to chemo- and/or radiation therapies. Resistance to apoptosis mainly causes this insensitivity to conventional therapies. Apoptosis or programmed cell death is a central regulator of tissue homeostasis. Certain genetic disturbances of apoptotic signaling pathways have been found in carcinomas leading to tumor development and progression. In the past few years, the knowledge about the complex pathways of apoptosis has strongly increased and new therapeutic approaches based on this knowledge are being developed. This review will focus on the role of apoptotic proteins contributing to pancreatic cancer development and progression and will demonstrate possible targets to influence this deadly disease. © 2003 Westphal and Kalthoff; licensee BioMed Central Ltd.

引用

页数：14

共 160 条

[1]

Parker S.L., Tong T., Bolden S., Wingo P.A., Cancer statistics, CA Cancer J. Clin., 47, pp. 5-27, (1997)

[2]

Coppola D., Molecular prognostic markers in pancreatic cancer, Cancer Contr., 7, pp. 421-427, (2000)

[3]

von Bernstorff W., Spanjaard R.A., Chan A.K., Lockhart D.C., Sadanaga N., Wood I., Peiper M., Goedegebuure P.S., Eberlein T.J., Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand, Surgery, 125, pp. 73-84, (1999)

[4]

Beger H.G., Bchler M.W., Friess H., Surgical results and indications for adjuvant measures in pancreatic cancer, Chirurg, 65, pp. 246-252, (1994)

[5]

Guo X., Friess H., Graber H.U., Kashiwagi M., Zimmermann A., Korc M., Buchler M.W., KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases, Cancer Res., 56, pp. 4876-4880, (1996)

[6]

Friess H., Buchler M., Kruger M., Beger H.G., Treatment of duct carcinoma of the pancreas with the LH-RH-analogue buserelin, Pancreas, 7, pp. 516-521, (1992)

[7]

Andren-Sandberg A., Backman P.L., Andersson R., Results of adjuvant therapy in resected pancreatic cancer, Int. J. Pancreatol., 21, pp. 31-38, (1997)

[8]

Palmer K.R., Kerr M., Knowles G., Cull A., Carter D.C., Leonard R.C., Chemotherapy prolongs survival in inoperable pancreatic carcinoma, Br. J. Surg., 81, pp. 882-885, (1994)

[9]

von Bernstorff W., Voss M., Freichel S., Schmid A., Vogel I., Johnk C., Henne-Bruns D., Kremer B., Kalthoff H., Systemic and local immunosuppression in pancreatic cancer patients, Clin. Cancer Res., 7, (2001)

[10]

Ungefroren H., Voss M., Jansen M., Roeder C., Henne-Bruns D., Kremer B., Kalthoff H., Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis, Cancer Res., 58, pp. 1741-1749, (1998)

← 1 2 3 4 5 6 7 8 9 10 →